CLINICAL STUDIES - JUNE 2008
 Dr
Jai Grewal and Dr Paul Duic will be conducting clinical
studies
Study Criteria: Patients must have a confirmed
glioblastoma, accomplished by tumor tissue laboratory
evaluation
Title: Phase III Trial Comparing Conventional
Adjuvant Temozolomide with Dose-Intensive Temozolomide
in Patients with Newly Diagnosed Glioblastoma
Protocol: RTOG 0525
SNCH Co-Investigators: Jai Grewal, M.D., and J.
Paul Duic, M.D.
Sponsor: Radiation Therapy Oncology Group
Objective: To determine if increasing the “dose-density” of
the temozolomide during chemoradiation, as compared with
conventional temozolomide dosing during chemoradiation,
enhances overall survival for persons with newly diagnosed
glioblastoma. The study will also compare the
treatment outcomes for patients with different genetic
makeup (patients with MGMT gene methylation vs those
with unmethylated MGMT genes).
.
For more information or to see if one qualifies for
this study, call 516-478-0010 or 631-864-3900.
For more information or to see if one qualifies
for this study, call 516-478-0010 or 631-864-3900.
|
